Department of Pharmacology, KG College of Pharmacy and Research Institute-605 203.
World Journal of Advanced Research and Reviews, 2026, 29(02), 631-644
Article DOI: 10.30574/wjarr.2026.29.2.0330
Received on 31 December 2025; revised on 09 February 2026; accepted on 11 February 2026
Alzheimer’s complaint (announcement) is the most common habitual neurodegenerative complaint worldwide and a leading cause of madness. It results in cognitive impairments similar as aphasia and agnosia, along with behavioral and cerebral symptoms that place a significant emotional and fiscal burden on cases and their families. First described by Alois Alzheimer in 1907, announcement is classified into domestic and sporadic forms. presently, over 47 million people are affected encyclopedically, with figures anticipated to rise sprucely by 2050. The complaint is characterized by amyloid pillars and neurofibrillary befuddlements formed by amyloid- β and tau proteins. Announcement is multifactorial, with the cholinergic and amyloid suppositions being central to its pathogenesis. This review summarizes recent advances in announcement mechanisms, memory impairment, opinion, treatment strategies, and ongoing clinical exploration.
Alzheimer’s; Dementia; Cognitive Impairment; Tau Protein; Amyloid Beta
Get Your e Certificate of Publication using below link
Preview Article PDF
J. Aruna, A. Lokesh, G. Madhavan V. Dhanalakshmi, R. Guhan, S. Kaviya, A.Sanjay, P. Saranyadevi and P. Surekha. The review on versatile study of Alzheimer’s Disease (AD) and their etiology, pathophysiology, common mechanism of action of drugs used in current treatment. World Journal of Advanced Research and Reviews, 2026, 29(02), 631-644. Article DOI: https://doi.org/10.30574/wjarr.2026.29.2.0330.
Copyright © 2026 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0